Clinical Trials Sponsored by Alpha Biopharma (Jiangsu) Co., Ltd.

Total 1316 results

Sir Run Run Shaw Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma

Metastatic Gastric Adenocarcinoma

China
L & L biopharma Co., Ltd., Shanghai China
Shanghai East Hospital

Not yet recruiting

A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors (TRIGGERCD8)

Solid Tumor

China
Shanghai Mental Health Center
Changchun Huayang High-tech Co., Ltd; Jiangsu Sheneryang High-tech Co., Ltd

Unknown

Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease

Alzheimer Disease

China
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
PPD Development, L.P.

Recruiting

DZD9008 PK Study in Hepatic Impairment Subjects

Hepatic Impairment

United States
Tianjin Medical University General Hospital
Jiangsu Bioperfectus Technologies Co., Ltd

Not yet recruiting

Research on Vaginal Microbiota Evaluation Unified Standards Based on Gram Staining (VENUS)

Vaginal Infection
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)

Advanced Breast Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer

Limited Stage Small Cell Lung Cancer

China
Zhigang Li
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial Of Neoadjuvant Chemotherapy or Radiochemotherapy With Or Without SHR-1210 In Patients With Resectable ESCC.

Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

China
Baohui Han
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns (APPOINT)

Lung Cancer

China
Qilu Hospital of Shandong University
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer

Early Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Peking University Cancer Hospital & Institute

Recruiting

A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms

Relapsed or Refractory Mature Lymphoid Neoplasms

China
Qun Zhao
Jiangsu HengRui Medicine Co., Ltd.

Completed

Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Clinical Study

Gastric Cancer

China
Shandong Cancer Hospital and Institute
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma | Second-line Treatment

China
Tianjin Medical University Second Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

Solid Tumor | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein Overexpression

China
Jiangsu HengRui Medicine Co., Ltd.
Shanghai Pulmonary Hospital, Shanghai, China

Completed

A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

China
Yanqiao Zhang
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC (HZ-T-PD1-APA)

Hepatocellular Carcinoma
Peking University First Hospital
Jiangsu Wanbang Pharmaceutical Marketing Co.,Ltd.

Unknown

Efficacy of Dun Ye Guan Xin Ning Tablet in Patients With Stable Angina Pectoris

Coronary Heart Disease

China
Jiangsu HengRui Medicine Co., Ltd.
Peking University Cancer Hospital & Institute

Unknown

A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients

Melanoma

China
Peking University Cancer Hospital & Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients

Hepatocellular Carcinoma

China
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer (AHEAD-G202)

Metastatic Gastric Cancer

China
Zhejiang University
Beta Pharma, Inc.; Jiangsu Simcere Pharmaceutical Co., Ltd.

Unknown

Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations

Lung Cancer

China
Jiangsu Kanion Pharmaceutical Co., Ltd
Beijing University of Chinese Medicine

Unknown

A Clinical Trial To Evaluate Reduning Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease

Hand, Foot and Mouth Disease

China
The First Affiliated Hospital of Zhengzhou University
BeiGene; Jiangsu Hengrui Pharmaceutical Co., Ltd.; RemeGen Co., Ltd.

Not yet recruiting

Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy

HER2-positive or Mutated Advanced Colorectal Cancer
Second Affiliated Hospital of Nanchang University
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis (ATTRACT)

NSCLC | EGFR Activating Mutation | Leptomeningeal Metastasis

China
Weill Medical College of Cornell University
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors

Thymic Carcinoma

United States
Jiangsu Simcere Pharmaceutical Co., Ltd.
The First People's Hospital of Lianyungang

Unknown

Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients

Esophageal Cancer

China
Xiangya Hospital of Central South University
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke (EARLYS)

Ischemic Stroke, Acute | Treatment Outcome

China
Nanfang Hospital of Southern Medical University
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

Iguratimod Combined With Tofacitinib in the Treatment of Rheumatoid Arthritis

Rheumatoid Arthritis
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Completed

Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

China
First Affiliated Hospital Xi'an Jiaotong University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer (CCWSA/OAFLAG)

Locally Advanced Gastric Cancer

China
Jiangsu Simcere Pharmaceutical Co., Ltd.
Second Hospital of Shanxi Medical University

Completed

A Pilot Bioequivalence Study of Pomalidomide

Bioequivalence

China
First Affiliated Hospital of Zhejiang University
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Completed

A Clinical Trial to Evaluate the Safety and Tolerability of Dexlansoprazole Injection in Healthy Chinese Adults (Part 1)

Safety Issues
Huabo Biopharm Co., Ltd.
First Affiliated Hospital Bengbu Medical College

Recruiting

A Study of HB0030 Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
YANRU WANG
Rui Therapeutics Co., Ltd

Recruiting

A Clinical Study of CD19 CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases

Autoimmune Diseases

China
Nanfang Hospital of Southern Medical University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients (PANORAMA)

Chemotherapy | Immunotherapy

China
The Affiliated Hospital of Qingdao University
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer

Breast Cancer
Nanfang Hospital of Southern Medical University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）

Hepatocellular Carcinoma

China
The Central Hospital of Lishui City
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Safety Evaluation of Linear and Macrocyclic Gadolinium Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging

Nephrogenic Fibrosing Dermopathy

China
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Thoracic Neoplasms | Non-small-cell Lung Cancer

China
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Thoracic Neoplasms | Non-Small-Cell Lung

China
First Affiliated Hospital of Zhejiang University
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Unknown

A Clinical Trial to Evaluate the Safety and Tolerability of Dexlansoprazole Injection in Healthy Chinese Adults（Part 2）

Safety Issues | Effect of Drugs

China
Jiangsu Simcere Pharmaceutical Co., Ltd.
The First People's Hospital of Lianyungang

Unknown

Continuous Endostar Infusion Combined With Radiotherapy in Patients With Brain Metastases

Brain Metastases

China
Cancer Institute and Hospital, Chinese Academy...
Jiangsu Hansoh Pharmaceutical Co., Ltd.; GeneCast Biotechnology Co., Ltd.

Enrolling by invitation

Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection (APEX)

Non-small Cell Lung Carcinoma

China
Rutgers, The State University of New Jersey
Adlai Nortye Biopharma Co., Ltd.

Not yet recruiting

A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

Lung Cancer Stage III

United States
The First Affiliated Hospital of Xiamen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma | Bevacizumab | TACE | Adebrelimab | Transformation

China
The First Affiliated Hospital of Zhengzhou University
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Clinical Study of Herombopag in Tumors-associated Thrombocytopenia

Tumor Therapy-related Thrombocytopenia
The First Affiliated Hospital of Zhengzhou University
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer

China

Clinical Trials Sponsored by Alpha Biopharma (Jiangsu) Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations